Colorectal Cancer

The identification of microsatellite status, tumor mutational burden and protein expression in colorectal cancer (CRC) tumors may lead to better outcomes in a subgroup of patients.

Patients with microsatellite instability-high (MSI-H) colorectal cancer may undergo a distinct pattern of clonal evolution, which in turn, would impact the use of targeted and immunologic therapies in these patients, according to study results presented at the 2018 Gastrointestinal Cancer Symposium.

Patients previously treated for DNA mismatch repair (MMR)-deficient/microsatellite instability-high (MSI-H) metastatic colorectal cancer may have a new effective treatment option.

Texas Rangers third-base coach Tony Beasley teams up with Fight CRC, sharing his journey into survivorship and inspiring others in their fight against cancer.

Genetic testing – particularly for microsatellite instability (MSI) – is an important step for all patients diagnosed with colorectal cancer.

In recent years, next-generation sequencing has allowed physicians and researchers alike to gather more genetic data for patients with gastrointestinal cancers. And while this kind of profiling continues to advance, so do treatment options for this patient population.

Luis A. Diaz, M.D., head of the division of Solid Tumors at Memorial Sloan Kettering Cancer Center, discusses response rates in patients with microsatellite instability-high (MSI-H) or NTRK fusion gastrointestinal (GI) cancers.

“The very exciting field of checkpoint inhibitors is still evolving, and we are trying to understand where they fit in the world of CRC therapy,” said McCollum, a hematologist and medical oncologist at Texas Oncology.

A recent study found that the cost to patients with breast, lung and colorectal cancers treated in the hospital outpatient setting was nearly $8,000 more than those treated in the community setting.

National non-profit begins a new chapter revealing new name, logo, and inclusive mission.

Nutrition plays a crucial role in the lives of people with cancer. But more than a million people suffering from the disease in the United States also endure a wasting syndrome called cachexia.

Researchers might be on to a new biomarker for patients with colorectal cancer, says Martin D. Berger, M.D., oncologist at the University of Southern California.

We’re moving into a new era of understanding with genetic abnormalities in colorectal cancer (CRC) as researchers continue to investigate tumor sidedness and the role of microsatellite instability (MSI) testing.

Opdivo (nivolumab) was granted approval by the Food and Drug Administration (FDA) for the treatment of both adult and pediatric patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) who have progressed following treatment with a fluoropyrimidine, oxaliplatin and irinotecan.

Holocaust survivors had higher rates of lung and colorectal cancer, according to a recent study.

Healthy weight, eating habits and exercise routines all led to a decreased chance of death for patients with colorectal cancer, according to a recent study.

Matthew Yurgelun, M.D., answers questions such as: Which patients with colorectal cancer should recieve molecular testing, and at what point?

In a recent study, people with certain disabilities were found to be less likely to follow recommended guidelines for colorectal cancer screening.

Daily or weekly aspirin regimens may have a positive effect on colorectal cancer outcomes, a recent study found.

Mutations might be the answer as to why sidedness has an effect on colorectal cancer outcomes.

What role will immunotherapy play in the future treatment of GI cancers? CURE spoke to Brian Hemphill, M.D., to find out.

Whether a cancer arises on the left or right side of the colon can affect both prognosis and treatment.